[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-nodule\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-nodule":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,49,87,113,134,165,189,214,235,259,281,308,329,351,378,398,417,444,469,498,528,551,577],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100625855","postoperative-hypocalcemia-after-thyroidectomy-100625855",false,"NCT07428057","Postoperative Hypocalcemia After Thyroidectomy","A Ten-Year Cohort Study of Clinical and Surgical Predictors for Hypocalcemia Post-Thyroidectomy","Inclusion Criteria:\n\n* Adult patients aged 18 years or older at time of surgery\n* Underwent thyroidectomy at Minia University Hospital\n* Availability of medical records with complete surgical and postoperative data\n* Documented serum calcium levels measured postoperatively\n* Minimum follow-up of 6 months postoperatively or documented outcome status\n\nExclusion Criteria:\n\n* Age less than 18 years at time of surgery\n* Preoperative hypocalcemia (serum calcium \\\u003C8.0 mg\u002FdL or ionized calcium \\\u003C1.0 mmol\u002FL)\n* Pre-existing parathyroid disorders (primary hyperparathyroidism, hypoparathyroidism, secondary or tertiary hyperparathyroidism)\n* Chronic kidney disease Stage 3 or higher (estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Malabsorption syndromes affecting calcium metabolism (celiac disease, inflammatory bowel disease,short bowel syndrome)\n* Concurrent planned parathyroidectomy\n* History of neck irradiation\n* Chronic use of medications significantly affecting calcium metabolism (bisphosphonates, denosumab,cinacalcet, chronic corticosteroids)\n* Incomplete medical records lacking essential data including surgical details, postoperative calcium levels,or follow-up data\n* Patients lost to follow-up before 6-month endpoint without documented outcome status","ALL","18 Years","75 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","This retrospective cohort study investigates predictors of postoperative hypocalcemia following thyroidectomy procedures at Minia University Hospital over a 10-year period (2014-2024). Postthyroidectomy hypocalcemia is one of the most common complications of thyroid surgery, affecting 20-50% of patients. The study aims to identify demographic, clinical, laboratory, and surgical factors associated with the development of both transient and permanent hypocalcemia. Results will inform risk stratification, patient counseling, and perioperative management strategies.",[25,26,27,28,29],"Thyroid Nodule","Thyroid Dysfunction","Hypocalcemia","Thyroid Cancer","Postoperative Complications",[31,32,33,34,35],"Thyroidectomy","Postoperative hypocalcemia","Hypoparathyroidism","Parathyroid gland injury","Total thyroidectomy","RECRUITING","2026-06-27",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2026-03-04",{"date":44,"type":21},"2026-08-01",{"name":46,"class":47},"Minia University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":48},"100640349","niraf-guided-parathyroid-identification-during-thyroidectomy-100640349","NCT07617584","NIRAF-Guided Parathyroid Identification During Thyroidectomy","Near-Infrared Autofluorescence-Guided Parathyroid Identification During Thyroidectomy","Inclusion Criteria:\n\n* Age 18 years or older.\n* For Component A: planned thyroidectomy of any extent with an intact specimen available for ex vivo evaluation.\n* For Component B: planned total or completion thyroidectomy.\n* Ability to provide written informed consent before surgery.\n* Willingness to comply with routine postoperative laboratory testing and follow-up when feasible.\n\nExclusion Criteria:\n\n* Known pre-existing hypoparathyroidism or prior parathyroid surgery.\n* Severe chronic kidney disease or end-stage renal disease expected to substantially confound calcium and parathyroid hormone interpretation, as defined by the site investigator.\n* Pregnancy.\n* For Component B only: gross nodal disease or a surgical plan requiring extensive nodal packet dissection in the current study phase.\n* Any condition that, in the judgment of the investigator, would make participation unsafe or compromise protocol adherence.",{"count":57,"type":21},280,"INTERVENTIONAL",[60],"NA","This is a single-site, two-component prospective study evaluating whether near-infrared autofluorescence (NIRAF) imaging can improve intraoperative identification of parathyroid glands during thyroidectomy and reduce postoperative hypocalcemia.\n\nThe investigational platform is a modified wearable stereoscopic goggle system configured for label-free NIRAF imaging. Parathyroid tissue is excited with near-infrared light at approximately 780 nm and emits autofluorescence centered near 800 nm. No injected dye or external contrast agent is used. The goggles are used only during a brief mapping interval after thyroid exposure and for ex vivo interrogation of the resected thyroid specimen.\n\nComponent A is a prospective observational run-in validation cohort of 30 adults undergoing thyroidectomy of any extent. NIRAF-positive foci on the intact thyroidectomy specimen are suture-marked and correlated with targeted pathology.\n\nComponent B is a randomized clinical study of 250 adults undergoing total or completion thyroidectomy. Participants are randomized 1:1 to standard surgery or standard surgery plus brief in vivo NIRAF mapping, ex vivo specimen interrogation, and rescue autotransplantation when indicated. The primary outcome for Component B is transient biochemical hypocalcemia on postoperative day 1, defined using albumin-corrected serum calcium.",[27,33,63,64,25,31],"Thyroid Diseases","Goiter, Nodular",[66,67,68,69,31,70,71,72,73,74,75,76,77],"Near-Infrared Autofluorescence","NIRAF","Parathyroid Identification","Parathyroid Preservation","Completion Thyroidectomy","Total Thyroidectomy","Postoperative Hypocalcemia","Intact Parathyroid Hormone","iPTH","Rescue Autotransplantation","Wearable Imaging","Post-thyroidectomy hypocalcemia","NOT_YET_RECRUITING","2026-05-29",{"date":81,"type":40},"2026-06-01",{"date":81,"type":21},{"date":84,"type":21},"2029-12-01",{"name":86,"class":47},"Ss. Cyril and Methodius University of Skopje",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":95,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100572211","surgical-competency-for-robot-assisted-thyroidectomy-construction-and-validation-of-a-robotic-thyroidectomy-assessment-score-rtas-100572211","NCT06730321","Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodules with a maximum diameter not exceeding 6 cm\n* Participants with high cosmetic expectations\n* Participants underwent robotic thyroidectomy without open conversion\n\nExclusion Criteria:\n\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of distant invasion\n* Participants with fusion or fixed of lymph nodes in the neck",{"count":94,"type":21},200,"6 Months","To develop and validate a structured scoring tool (robotic thyroidectomy assessment score, RTAS) for assessing and quantifying surgical performance in robotic thyroidectomy (RT).",[28,25,63,98,99],"Thyroid Cancer, Papillary","Thyroid Cancer, Follicular",[101,102,103],"Robotic thyroidectomy","Surgical competency","Robotic thyroidectomy assessment score","2026-05-02",{"date":106,"type":40},"2026-05-07",{"date":108,"type":40},"2024-12-12",{"date":110,"type":21},"2027-12-31",{"name":112,"class":47},"Shanghai 6th People's Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":48},"100572870","renovated-prediction-model-for-difficult-transoral-and-submental-endoscopic-thyroidectomy-100572870","NCT06738888","Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy","Renovated Prediction Model for Difficult. Transoral and Submental Endoscopic Thyroidectomy","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodule with a maximum diameter not exceeding 6 cm\n* Absence of suspicious lateral lymph nodes or distant metastases\n\nExclusion Criteria:\n\n* Participants with fusion or fixation of lymph nodes in the neck\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of extrathyroidal invasion\n* Participants with a significantly restricted neck and\u002For jaw",{"count":121,"type":21},300,"The investigators have previously proposed a prediction model for difficult transoral and submental thyroidectomy through a retrospective study. In order to better promote transoral and submental endoscopic approach for thyroid surgery and to set up an appropriate training course, the investigators aim to renovate and validate the prediction model through a prospective study.",[28,63,25],[125,126,127],"Endoscopic thyroidectomy","Transoral and submental approach","Prediction model",{"date":106,"type":40},{"date":130,"type":40},"2024-05-01",{"date":132,"type":21},"2028-12-31",{"name":112,"class":47},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":58,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":164},"100615021","prospective-evaluation-of-the-pulse-biosciences-npulse-vybrance-percutaneous-electrode-system-100615021","NCT07287176","Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System","Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System in Symptomatic Benign Thyroid Nodules (PRECISE-BTN) Study","PRECISE-BTN","Inclusion Criteria:\n\n* Participant is willing and able to provide voluntary, written informed consent to participate in this study and from whom written informed consent has been obtained\n* Participants must be willing and able to comply with study procedures including all follow-up visits\n* Selected nodule is amenable to trans-isthmus approach\n* Nodule is confirmed as benign based on results from one or more of the following diagnostic tests:\n\n  1. (Bethesda II) on at least 2 ultrasound guided fine needle aspirations (FNA) or core needle biopsy (CNB);\n  2. A single benign diagnosis of FNA or CNB when the nodule has benign ultrasound features \\[American College of Radiology (ACR) Thyroid Imaging Reporting \\& Data System \\[TI-RAD\\] TR 1-3, American Thyroid Association \\[ATA\\] very low suspicion\\];\n  3. Candidate has a hyperfunctional nodule following 1 ultrasound guided FNA or CNB with or without molecular testing; or\n  4. Benign (Bethesda III or IV) with two biopsies in addition to molecular testing confirming benign diagnosis\n* Selected nodule is \\\u003C80.0 ml\n* Participant has normal vocal cord mobility by ultrasound evaluation\n* Participant has presence of compression symptoms, cosmetic concerns or anxiety for which participant requests treatment of the benign thyroid nodule\n* Participant has a solitary thyroid nodule or dominating nodule that is well-defined in multinodular goiter\n\nExclusion Criteria:\n\n* Participant has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter defibrillator)\n* Participant has cystic nodules (\\\u003C 70% solid components)\n* Participant has calcified nodules\n* Participant is known to be immune compromised\n* Participant had previous neck irradiation\n* Participant has abnormal cervical lymph nodes present during screening visit examination\n* Participant has history of familial thyroid cancer in more than two first-degree relatives\n* Selected nodule previously treated with radiofrequency ablation or ethanol. This does not apply to nodules previously treated with nanosecond Pulsed Field Ablation (nsPFA)\n* Participants currently suffering from a hematological disease or bleeding tendency\n* Selected nodule likely to be in contact with the recurrent laryngeal nerve on ultrasound evaluation\n* Participant has a history of uncontrolled cardiac arrhythmia, uncontrolled hypertension, chronic liver disease or chronic kidney disease (Stage 4-5), or recent history of myocardial infarction or structural heart disease as determined by the Investigator\n* Participant has abnormal contralateral vocal cord function\n* Anesthesia drug allergies\n* Participant is pregnant at the time of screening or within 30 days prior to enrollment\n* Participant has any condition or situation which, in the Investigator's opinion, puts the participant at significant risk, could confound the study results, or may interfere significantly with the participant's participation in the study\n* Use of any investigational device or drug within 30 days prior to enrollment that may confound the results of this study","22 Years","80 Years",{"count":145,"type":21},100,[60],"The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.",[25,149,150],"Thyroid Goiter","Ablation",[152,153],"nsPFA","Pulsed Field Ablation","2026-04-13",{"date":156,"type":40},"2026-04-15",{"date":158,"type":40},"2025-08-21",{"date":160,"type":21},"2027-06-30",{"name":162,"class":163},"Pulse Biosciences, Inc.","INDUSTRY",3,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":48},"100630488","multimodal-assessment-of-malignancy-in-atypia-of-undetermined-significance-in-thyroid-nodules-using-ultrasound-and-cytology-whole-slide-images-100630488","NCT07488325","Multimodal Assessment of Malignancy in Atypia of Undetermined Significance in Thyroid Nodules Using Ultrasound and Cytology Whole-Slide Images","Inclusion Criteria:\n\n* (a) Patients who underwent fine-needle aspiration of thyroid nodules and received a cytological diagnosis of Bethesda Ⅲ.\n* (b) Patients who subsequently underwent thyroid surgery with a definitive histopathological diagnosis of benign or malignant lesions,.\n* (c) Availability of at least one ultrasound image acquired prior to surgery.\n\nExclusion Criteria:\n\n* (a) Patients without confirmation by surgical pathology,.\n* (b) Patients without any available or usable ultrasound images.",{"count":172,"type":21},396,"The prospective study aim to develop a multimodal deep learning model that integrates ultrasound images and cytological whole-slide images for more accurate malignant risk prediction of Bethesda III thyroid nodules.",[25],[25,176,177,178,179],"Atypia of Undetermined Significance","Multimodal Deep Learning","Ultrasound","Cytology Whole-Slide Image","2026-03-30",{"date":182,"type":40},"2026-04-01",{"date":184,"type":40},"2026-03-01",{"date":186,"type":21},"2026-07-15",{"name":188,"class":47},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":58,"phases":200,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":213},"100548610","phase-4-efficacy-and-safety-of-prunella-oral-liquid-in-the-treatment-of-thyroid-nodules-100548610","NCT06423235","Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules","Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study","ESPTTN","Inclusion Criteria:\n\n* 18 years old ≤65 years old;\n* Thyroid ultrasonography found thyroid nodules, may be accompanied by goiter, and the nodules meet the following conditions: 1) single nodules, or dominant nodules in multiple nodules (the largest diameter of the second largest nodules does not exceed 50% of the largest nodules), 2) solid nodules, 3) the longest diameter of nodules ≥1cm and \\\u003C 3cm, 4) C-TIRADS 3\\~4A nodules;\n* Patients who met the puncture indications were confirmed by fine needle aspiration biopsy (FNAB) as benign nodules (Bethesda Class II);\n* Serum TSH, free thyroid hormone (FT3, FT4) levels were normal, anti-thyroglobulin (TgAb) and anti-thyroid peroxidase (TPOAb) antibody titers were normal;\n* Meet the diagnostic criteria of thyroid nodules in TCM;\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Exclude the patients with Deficiency of Yang syndrome, and the following two conditions can be diagnosed: Shortness of breath, abdominal pain and diarrhea, diarrhea with undigested food, Insufficiency with chills, exhaustion and lethargy, pale tongue and white fur, deep and weak pulse\n* Those who have reproductive needs during pregnancy, lactation and within the last 12 months;\n* Patients with high possibility of thyroid cancer indicated by ultrasonic signs and malignant confirmed by fine needle biopsy;\n* Patients who meet the indications for thyroid nodule surgery, such as local compression symptoms obviously related to the nodule, the tumor is located behind the sternum or in the mediastinum, or strongly require surgery due to appearance or ideological concerns affecting normal life;\n* Patients who have taken prunella preparations or other similar Chinese medicines to treat the disease within the past 1 month; Patients using glucocorticoids in the last 3 months;\n* Patients who have had or plan to take thyroid hormone, iodine compound, or antithyroid drug therapy during the study period;\n* Patients who have previously or plan to undergo ablation, neck radiation, surgery and other non-drug treatments during the study period;\n* Patients with parathyroid tumor (PTA), medullary thyroid cancer (MTC) or other malignant tumors, or patients with serious cardiovascular disease, liver and kidney disease, osteoporosis, or patients with a history of mental illness;\n* Patients with a family history of thyroid cancer or thyroid cancer syndrome;\n* Laboratory test index ALT, AST \\> 1.5 times the upper limit of reference value or blood creatinine (Scr) \\> the upper limit of reference value;\n* Persons who are known to be allergic to the investigational drug or its ingredients;\n* Other patients determined by the investigator to be unsuitable for participation in the study.","65 Years",{"count":199,"type":21},234,[201],"PHASE4","A multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of Prunella oral liquid in patients with benign thyroid nodules, which belongs to the post-marketing reevaluation clinical study.\n\nIn this study, 234 subjects will be enrolled by competitive enrollment at several research centers across China. The main inclusion criteria are:\n\n① Thyroid ultrasound examination found thyroid nodules, can be accompanied by goiter, and the nodules meet the following conditions: 1) There were dominant nodules in single or multiple nodules (the largest diameter of the second largest nodules was not more than 50% of the largest nodules), 2) solid nodules, 3) the longest diameter of nodules was ≥1cm and \\\u003C 3cm, 4) C-TIRADS 3\\~4A nodules.\n\n② Patients who met the puncture indication were confirmed by fine needle aspiration biopsy (FNAB) as benign nodules (Bethesda II).\n\n③ Levels of TSH, FT3 and FT4 were normal, and the antibody titers of TgAb and TPOAb were normal.\n\nEligible subjects will be randomly assigned on a 1:1:2:2 scale to: Group A (placebo conventional dose group, 10 mL\u002Ftimes, 2 times\u002Fday), group B (placebo 2x dose group, 10ml\u002Ftimes, 2 times\u002Fday), group C (conventional dose group of Prunella oral liquid), group D (Prunella oral liquid 2x dose group). All subjects will receive the treatment for 9 months and follow up at 3rd, 6th, 9th and 12th month.\n\nThe primary efficacy endpoint of this study was the rate of change in thyroid nodule volume from baseline at 9 months of treatment. The rate of change in thyroid nodule volume from baseline at 3 and 6 months of treatment was a secondary efficacy endpoint. Other secondary efficacy endpoints included maximum thyroid nodule diameter, number of thyroid nodules, proportion of patients with reduced thyroid nodule volume or ≥50% from baseline, thyroid volume, thyroid function (serum TSH, FT3, FT4, thyroid egg levels (Tg), thyroid antibody levels (TgAb, TPOAb), quality of life evaluation (SF-36), etc. Safety endpoints included incidence of AE\u002F serious adverse events (SAE), causality, and outcomes. Incidence of AE\u002FSAE leading to discontinuation. Changes in safety laboratory test values from baseline.",[25],"2026-03-19",{"date":206,"type":40},"2026-03-24",{"date":208,"type":40},"2024-07-30",{"date":210,"type":21},"2028-07-30",{"name":212,"class":163},"Xintian Pharmaceutical",22,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":58,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":48},"100533041","trail-study-feasibility-and-pilot-100533041","NCT06220656","TRAIL Study: Feasibility and Pilot","ThyRoid Active Monitoring and Intervention Longitudinal (TRAIL) Study: Feasibility and Pilot","Inclusion Criteria:\n\n* Participants must be ≥18 years of age.\n* Participants must be able and willing to provide informed consent or have a surrogate capable of providing same.\n* Participants must be absent of symptoms referable to the nodule: dysphagia or nodule physically visible and\u002For bothersome to patient.\n* Participants' thyroid nodule must have a TI-RADS rating of 4 or 5.\n* Participants thyroid nodule must be ≤2 cm in largest diameter.\n* Participants must be being considered for biopsy.\n* Participants with a prior history of papillary thyroid cancer are eligible.\n\nExclusion Criteria:\n\nPatients who fall into one of the following categories will NOT be eligible for this study:\n\n* Adults who are unable to provide informed consent.\n* Patients for whom biopsy is not a consideration.\n* Patients with a prior history of thyroid cancer other than papillary thyroid cancer.\n* Patients with a history of radiation to the neck.\n* Patients who are athyroidal (thyroid gland has been removed or patient has only lingual thyroid tissue).\n* Patients who have ultrasound evidence of one or more of the following:\n* Airway invasion of the nodule.\n* Nodule adjacency to\u002Finvading the recurrent nerve.\n* Extra-thyroidal invasion by the nodule.\n* Patients who have metastasis to cervical lymph nodes (confirmed by needle biopsy if ultrasound suspicious), distant metastases, if identified) testing not required, not usual care)\n* Patients who have already had a biopsy of the nodule being considered for inclusion in the study.\n\nTRAIL Pilot Integrated QRI: Inclusion\u002FExclusion Criteria\n\nInclusion Criteria for Study Patient Participants:\n\n* Participants must meet the eligibility requirements above and will be or have been approached about enrolling in the pilot study.\n* Participants must be willing to allow audio recorder presence and \u002F or willing to be interviewed by the QRI team.\n\nExclusion Criteria for Study Patient Participants:\n\n-Patients who are not willing to allow audio recorder presence and\u002For not willing to be interviewed by QRI team will be excluded from this study.\n\nInclusion Criteria for Study Staff Participants:\n\n* Staff must be willing to audio record their communications with patients about enrolling in the study.\n* Staff must be willing to participate in interviews with QRI team about their views of the study.\n\nExclusion Criteria for Study Staff Participants:\n\n-Staff members who are not willing to participate in audio taping of recruitment discussions and\u002For interviews with QRI team about their views of the study will be excluded.",{"count":222,"type":21},20,[60],"This is a pilot study to compare two ways of managing newly identified thyroid nodules that are likely to be cancerous based on ultrasound result and which under usual care would undergo immediate biopsy.\n\nThe main goals of this pilot study are 1) compare anxiety at 6 months in each treatment arm using the validated instrument Anxiety-CA, 2) measure thyroid quality of life in each treatment arm\n\nParticipants will be randomized to one of two groups:\n\n1. immediate biopsy (usual care)\n2. Active monitoring (serial ultrasound based monitoring and close clinical follow-up)",[25,226,28],"Thyroid Neoplasms",{"date":228,"type":40},"2026-03-23",{"date":230,"type":40},"2025-05-01",{"date":232,"type":21},"2027-06",{"name":234,"class":47},"Dartmouth-Hitchcock Medical Center",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":48},"100527361","ceus-improves-the-diagnostic-performance-of-srss-of-thyroid-carcinoma-100527361","NCT06146764","CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma","Contrast-enhanced Ultrasound Improves the Diagnostic Performance of Sonographic Risk Stratification System of Thyroid Carcinoma: Comparison Between Integrated Scoring Method and Up-and-down Scoring Method","Inclusion Criteria:\n\n* Participants with thyroid nodules with a solid component ≥5 mm confirmed by conventional ultrasound;\n* Participants who underwent conventional ultrasound, contrast-enhanced ultrasound, and fine-needle aspiration biopsy;\n* Participants with a final benign or malignant pathological results.\n\nExclusion Criteria:\n\n* Participants with cytopathology of Bethesda I, III, or IV and without final benign or malignant pathology；\n* Participants with a history of thyroid ablation or surgery;\n* Participants with low-quality ultrasound images.",{"count":243,"type":21},800,"Contrast-enhanced ultrasound (CEUS) can sensitively show the blood perfusion characteristics of thyroid nodules, which is a useful supplement to gray-scale ultrasound. However, there is no standard combined diagnostic method of gray-scale ultrasound and CEUS. Therefore, the aim of this study was to compare the diagnostic performance of the integrated scoring method and the up-and-down scoring method. This study was a multicenter retrospective clinical study and followed the Standards for Reporting of Diagnostic Accuracy Studies (version 2015). Inclusion criteria: 1) participants with at least one thyroid nodule larger than 5 mm confirmed by conventional ultrasound; 2) participants underwent gray-scale ultrasound, contrast-enhanced ultrasound and fine needle aspiration biopsy of the thyroid nodule successively; 3) participants have a final diagnosis of benign or malignant. Exclusion criteria included: 1) participants with cytologic findings of Bethesda I, III, or IV without definitive benign or malignant pathologic findings; 2) participants with a history of thyroid fine needle aspiration, ablation or surgery; 3) participants with low quality ultrasound images (e.g., severe artifacts or low image resolution). According to the American College of Radiology Thyroid Imaging Reporting and Data System, only one thyroid nodule with the highest point was included in each participant. A total of 600 participants from January 2018 to December 2022 were consecutively included in Sun Yat-sen Memorial Hospital of Sun Yat-sen University to form a training set (average age 48 years; Range 24-81 years old). A total of 200 subjects with thyroid nodules from January 2022 to December 2022 were consecutively included to form an external validation set in Houjie Hospital of Dongguan City, Guangdong Province (mean age 46 years; Range 30-74 years). The malignant risk of enrolled thyroid nodules and the necessity of biopsy were evaluated by integrated scoring method and up-and-down scoring method, respectively. The diagnostic performance and unnecessary biopsy rate of the above two methods were calculated and compared.",[25,246],"Thyroid Carcinoma",[25,248,249,250,251],"Contrast Media","Gray-scale Ultrasound","Diagnosis","Biopsy","2026-03-18",{"date":228,"type":40},{"date":255,"type":40},"2023-03-18",{"date":257,"type":21},"2026-07-31",{"name":188,"class":47},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":266,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":58,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":48},"100621442","active-surveillance-for-bethesda-iv-thyroid-nodules-100621442","NCT07370675","Active Surveillance for Bethesda IV Thyroid Nodules","Active Surveillance for Small Thyroid Nodules With Bethesda IV Cytology: A Prospective Cohort Study Protocol","Inclusion Criteria:\n\n* age of 30 years or older AND\n* a single nodule with a Follicular neoplasm or suspicious for a follicular neoplasm (category IV in the Bethesda system) AND\n* tumor size of less than 2 cm in all dimensions AND\n* EU-TIRADS 3 or 4 in Ultrasound imaging examination.\n\nExclusion Criteria:\n\n* EU-TIRADS 5 in Ultrasound imaging examination.\n* suspicion of disseminated disease because of PET-positive lymph nodes; suspect lymph-nodes by US or by CT-scan; or signs of capsular invasion of the tumor, or irregular shape or margins, extrathyroidal growth OR\n* tumor placement at a high-risk location (in the thyroid capsule with extracapsular extension toward vessels, RLN, or the trachea) OR\n* previous thyroid surgery OR\n* concomitant hyperparathyroidism (ionized calcium \\> 1.32 mmol\u002FL and PTH \\> 6 pmol\u002FL) OR\n* if the patient is pregnant OR\n* If the patient is unable to give informed consent. OR\n* If calcitonin is elevated above normal level","30 Years",{"count":268,"type":21},165,[60],"The traditional surgical approach for Bethesda IV thyroid nodules burdens healthcare systems and patients with costs, perioperative morbidity, and potential long-term consequences of hemithyroidectomy, including hypothyroidism (requiring lifelong thyroid hormone replacement), nerve damage, infection, voice discomfort and postoperative bleeding. Moreover, patient-reported anxiety and reduced quality of life often follow surgery, regardless of benign final pathology. Conversely, surveillance strategies that include periodic ultrasound assessment, clinical examination, and patient education may reduce overtreatment, preserve thyroid function, and optimize resource utilization.\n\nThis prospective cohort protocol seeks to address these gaps by systematically evaluating the safety, feasibility, patient experience, and clinicopathologic predictors of progression for Bethesda IV nodules \\\u003C2 cm managed with active surveillance.\n\nOur hypothesis is: In patients with thyroid nodules smaller than 2 cm and cytology consistent with Bethesda IV, active surveillance is a safe and feasible alternative to immediate surgery. We hypothesize that only a minority of patients will demonstrate clinically significant tumor progression or require surgical intervention within five years, and that prospective surveillance can prevent unnecessary thyroid operations without compromising patient safety or long-term outcomes.\n\nThe primary aim of this study is to determine the proportion of patients with Bethesda IV thyroid nodules \\\u003C2 cm who undergo surgical intervention or experience disease progression over a 1-, 2- and 5 year AS period.",[28,25],"2026-01-19",{"date":274,"type":40},"2026-01-27",{"date":276,"type":40},"2026-01-16",{"date":278,"type":21},"2033-01-16",{"name":280,"class":47},"Christian Grønhøj Larsen",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":288,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":58,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":307},"100613718","a-study-of-multiparametric-ultrasound-imaging-methods-100613718","NCT07270237","A Study of Multiparametric Ultrasound Imaging Methods","Development and Evaluation of Ultrasound Imaging Acquisition and Analysis Methods","Inclusion Criteria:\n\n* Cohort 1 - Feasibility of multiparametric endoscopic ultrasound (mpEUS) imaging of patients at high-risk for pancreatic cancer:\n\nPatient Group: those having standard endoscopic ultrasounds because they are at high risk of pancreatic cancer Participants enrolled into the Memorial Sloan Kettering Cancer Center Pancreatic Registry protocol (IRB#: 02-102) will be eligible for this study. Specifically, related individuals without pancreatic cancer who are at-risk for developing pancreatic cancer and meet all of the following criteria (family health history will be self-reported):\n\n* 10 years younger than the earliest pancreatic cancer diagnosis in the family\n* Be at least 50 years old\n* Be at least 40 years old if diagnosed with FAMMM syndrome (CDKN2A\u002Fp16) or Hereditary Pancreatitis (PRSS1, SPINK1\u002FPST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes)\n* Be at least 35 years old if diagnosed with Peutz-Jeghers syndrome (STK11 aka LKB1)\n* Not pregnant and not Nursing\n* Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined by the project leader (Dr. Vineet Rolston)\n* Must agree to be contacted for follow-up\n* Must satisfy at least one of the following 4 criteria:\n\n  1. Have at least two affected relatives who are a first-degree relative to each other, of whom at least one is a first degree relative to the individual OR have at least two affected first-degree relatives on the same side of the family.\n  2. Have at least one first- or second-degree affected relative and have germline genetic test results that confirm a likely pathogenic or pathogenic variant in at least one of the following genes:\n\n     1. APC (Familial Adenomatous Polyposis (FAP) and Attenuated FAP syndrome\n     2. BRCA1(Hereditary Breast and Ovarian Cancer Symptoms)\n     3. MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch Syndrome)\n     4. PALB2\n     5. TP53 (Li-Fraumeni Syndrome)\n     6. Other established pancreatic cancer predisposition gene per project leader's discretion\n  3. Have germline genetic test results that confirm a likely pathogenic or pathogenic variant in one or more of the following genes:\n\n     1. CDKN2A\u002Fp16 (Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM))\n     2. STK11 aka LKB1 (Peutz-Jeghers Syndrome)\n     3. PRSS1, SPINK1\u002FPST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes per project leader's discretion\n     4. ATM (ataxia telangiectasia mutated)\n     5. BRCA 2(Hereditary Breast and Ovarian Cancer Symptoms)\n  4. Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined the project leader (Dr. Vineet Rolston)\n\nCohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:\n\nPatient Group: those with pancreatic cancer having endoscopic ultrasound-guided biopsies\n\nPatients will be entered into the study if they meet the following criteria:\n\n* Patients with pancreatic ductal adenocarcinoma\n* Are undergoing endoscopic ultrasound-guided tissue core biopsy as part of their standard of care\n* Not pregnant and not nursing\n\nCohort 3 - Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging:\n\nPatient Group: those with a thyroid nodule that will be biopsied whether they have known cancer or not\n\n* Are undergoing ultrasound-guided thyroid biopsy as part of their standard of care\n* Not pregnant and not nursing\n\nHealthy Volunteers will be entered into the study if they meet the following criteria:\n\n* No known cancer diagnosis or thyroid nodules\n* Age ≥ 18\n* Able to understand and give informed consent\n* Not pregnant and not nursing\n\nExclusion Criteria:\n\nCohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:\n\n* Unable to sign an informed consent for medical or other reasons; residents outside the continental United States\n* Under 18 years of age\n\nCohort 3 -Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging\n\n* Unable to sign an informed consent for medical or other reasons; residents outside the continental United States\n* Under 18 years of age",true,{"count":290,"type":21},85,[60],"The researchers are doing this study to see how well a type of ultrasound imaging called multiparametric ultrasound (mpUS), can be used to examine, evaluate, and provide information about different cancerous and non-cancerous tissue. The researchers will compare the results of mpUS imaging to standard ultrasound imaging and other standard tests.\n\nmpUS imaging is a type of ultrasound imaging that combines different ultrasound methods and analysis to create a more detailed and accurate assessment of tissue. Standard ultrasound provides a basic image of tissue structure, but mpUS imaging can also show blood vessels, blood flow, and detailed tissue structure (microstructure). The researchers think that mpUS may be a better way for evaluating cancer because it combines different ultrasound methods to assess tissue.",[294,25],"Pancreatic Cancer",[178,296,297],"mpUS","25-299","2025-12-05",{"date":300,"type":40},"2025-12-12",{"date":302,"type":40},"2025-11-24",{"date":304,"type":21},"2027-11",{"name":306,"class":47},"Memorial Sloan Kettering Cancer Center",7,{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":58,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":48},"100459610","decision-aid-and-thyroid-nodules-management-100459610","NCT05264857","Decision Aid and Thyroid Nodules Management","Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer","Inclusion Criteria:\n\n* Histology showing indeterminate or malignant thyroid pathology (Bethesda III-VI)\n* Thyroid nodule size less or equal to 2cm\n\nExclusion Criteria:\n\n* History of thyroid surgery\n* History of thyroid cancer",{"count":316,"type":21},134,[60],"Patients with small favorable malignant or indeterminate thyroid nodules will receive information about management of thyroid nodules. Participants will be asked to complete brief surveys at the time of enrollment, shortly after the consultation appointment with the surgeon, and a few months after either the consultation or the surgery, to assess their satisfaction with their decision and decision making process. All participants will receive routine care and counseling by their endocrinologist and surgeon.",[25],"2025-10-10",{"date":322,"type":40},"2025-10-14",{"date":324,"type":40},"2022-02-08",{"date":326,"type":21},"2027-09-30",{"name":328,"class":47},"Stony Brook University",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":58,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":48},"100508651","radiofrequency-ablation-study-in-latinx-patients-100508651","NCT05903196","Radiofrequency Ablation Study in LatinX Patients","Study of the Use of Radiofrequency Ablation in LatinX Patients With Symptomatic Benign Thyroid Nodules","Inclusion Criteria:\n\n* Subject capable of giving informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Subjects over 18 years of age\n* Subject who self-identifies as LatinX\n* Subjects who have a benign, symptomatic thyroid nodule\n* Subjects whose nodule has well-defined margin on ultrasound and is surrounded by at least 2mm of normal thyroid parenchyma in all directions\n\nExclusion Criteria:\n\n* Patients who are pregnant, trying to become pregnant, or breastfeeding\n* Patient who have a cardiac pacemaker,defibrillator , or other electromedical equipment\n* Patients who have a nodule that is malignant or not predominantly solid (must be \\>50% solid by ultrasound)\n* Patients who cannot give consent\n* Patients on anticoagulation or dual antiplatelet therapy\n* Patients with acute illness\n* People with BP \\> 140\u002F90 prior to the scheduled procedure","90 Years",{"count":338,"type":21},44,[60],"Benign thyroid nodules can still create cosmetic, compressive, or hormonal issues for patients. In the past, surgery was typically used to treat thyroid nodules causing the above issues through partial or complete thyroidectomy. More recently, minimally-invasive techniques have been developed to treat these issues. This study is investigating the use of one of these techniques, radiofrequency ablation, in Latinx patients with benign symptomatic thyroid nodules. This procedure is of interest because it avoids the risks of surgery and can be done outside an operating room. The study hypothesis is that the use of RFA is an effective and safe therapeutic option for LatinX patients with a symptomatic benign nodule wishing to avoid surgery.",[25],"2025-09-18",{"date":344,"type":40},"2025-09-23",{"date":346,"type":40},"2024-03-12",{"date":348,"type":21},"2025-12-30",{"name":350,"class":47},"Northwell Health",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":288,"sex":16,"minAge":17,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":58,"phases":361,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":48},"100587535","the-safety-and-feasibility-of-radiofrequency-ablation-to-treat-low-risk-thyroid-cancer-100587535","NCT06929650","The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer","Thermo-Ablation With Radiofrequency Medical Technologies to Treat Thyroid Cancers","Inclusion Criteria:\n\n1\\. Patients with:\n\n* Nodule less than or equal to 2cm in size\n\n  a. Specifically: Bethesda 5\u002F6\n* Their age is ≥18 years and ≤100 years\n* Able to provide written consent\n* Able to attend required follow-ups as per the protocol\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Pregnant women\n* Any concern for invasive or metastatic thyroid cancer\n* Previously treated for thyroid cancer","100 Years",{"count":360,"type":21},40,[60],"The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is:\n\n• What is the feasibility of RFA use for low-risk thyroid cancers (≤2 cm)?\n\nParticipants will undergo a set of pre-procedural scans of the target thyroid nodule and undergo the RFA procedure\u002Fintervention. Then, participants will partake in three follow-up appointments at 4 weeks, 6 months, and 12 months post-procedure as per standard of care.",[25,28],[365,366,367,368],"Radiofrequency Ablation","Feasibility","Adverse Event","Thyroid nodule","2025-04-08",{"date":371,"type":40},"2025-04-16",{"date":373,"type":40},"2023-04-20",{"date":375,"type":21},"2025-12-31",{"name":377,"class":47},"University Health Network, Toronto",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":397},"100572475","ultrasound-guided-thermal-ablation-for-bethesda-iiiiv-thyroid-nodules-100572475","NCT06733753","Ultrasound-guided Thermal Ablation for Bethesda III\u002FIV Thyroid Nodules","Ultrasound-guided Thermal Ablation for Bethesda III\u002FIV Thyroid Nodules: A Multicenter Study","Inclusion Criteria:\n\n1. confirmation of Bethesda III or IV on fine- needle aspiration and negative on Braf V600E test\n2. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest CT\n3. refusal or ineligibility for surgery\n4. follow-up time ≥12 months\n\nExclusion Criteria:\n\n1. follicular neoplasm or malignancy findings on biopsy\n2. no suspicious of malignancy in US\n3. patients with contra-lateral vocal cord paralysis\n4. follow- up time less than 12 months",{"count":20,"type":21},"To evaluate the long-term outcomes of ultrasound-guided thermal ablation for Bethesda III\u002FIV thyroid nodules",[25],"2025-02-13",{"date":390,"type":40},"2025-02-14",{"date":392,"type":40},"2024-12-09",{"date":394,"type":21},"2030-12-31",{"name":396,"class":47},"Chinese PLA General Hospital",2,{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":16,"minAge":404,"maxAge":143,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":4},"100576248","accuracy-of-fnac-in-diagnosis-of-thyroid-nodules-100576248","NCT06782828","Accuracy of FNAC in Diagnosis of Thyroid Nodules","Inclusion Criteria:\n\n1. thyroid disease\n2. multinodular\n3. single nodule\n4. TIRAD 3 or more by US\n5. thyroid disease underwent FNAC then surgery\n6. all age groups\n7. patient fit for surgery\n\nExclusion Criteria:\n\n1. patients with comorbidities.\n2. patients unfit for surgery\n3. patients who refused surgery.\n4. Patient with no diagnostic FNAC.","10 Years",{"count":145,"type":21},"Detection of degree of accuracy of FNAC in diagnosis of thyroid nodules",[25],"2025-01-17",{"date":410,"type":40},"2025-01-20",{"date":412,"type":21},"2025-03",{"date":414,"type":21},"2025-12",{"name":416,"class":47},"Assiut University",{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":58,"phases":427,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":48},"100572649","myo-inositol-and-selenium-in-indeterminate-thyroid-nodules-tir3a-100572649","NCT06736015","Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)","Use of Myo-inositol and Selenium in Patients with Indeterminate Thyroid Nodules (TIR3A)","MYOSEL","Inclusion Criteria:\n\n* Adult (\\>18 years old),\n* both sexes,\n* patients presenting thyroid nodules classified as TIR 3A, based on cytological evaluation on sample from the first fine needle aspiration (FNA),\n* written Informed consent,\n* Patients with appropriate material for subsequent immunocytochemical analysis of Ki-67 and PCNA\n\nExclusion Criteria:\n\n* Patients with diagnosed thyroid malignancies of cytological diagnosis other than TIR3A\n* pathological levels of the thyroid stimulating hormone (TSH) which required L-Thyroxine treatment starting\n* pregnancy and\u002For breastfeeding",{"count":426,"type":21},30,[60],"Thyroid nodules present a variable risk of malignancy depending on the cytological result obtained from the ultrasound-assisted thyroid fine needle aspiration biopsy. According to the Italian Cytology classification SIAPEC-IAP 2014, the TIR3A nodules are indeterminate nodules with a risk of malignancy lower than 10%. Clinical and instrumental follow-up is recommended in these cases, including repetition of the fine needle aspiration.\n\nA study have demonstrate the effect of a six-month treatment with a supplement containing myo-inositol and selenium on the size and elasticity of benign thyroid nodules.\n\nOur hypothesis is that the use of this supplement can determine a reduction in the size and consistency of the nodule assessed through ultrasound and elastosonography also in cytologically indeterminate (TIR3A) nodules and that treatment can reduce the cellular proliferation of these nodules assessed by immunocytochemistry.\n\nTherefore, we design a prospective randomized pilot study to assess efficacy and safety of myo-inositol and selenium in TIR3a thyroid nosules, comparing treated and untreated patients.",[25],[431,432,433,434],"TIR3A","indeterminate thyroid nodules","myo-inositol","selenium","2024-12-13",{"date":437,"type":40},"2024-12-16",{"date":439,"type":40},"2024-10-23",{"date":441,"type":21},"2026-10-30",{"name":443,"class":47},"Regina Elena Cancer Institute",{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":452,"conditions":453,"keywords":454,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":468},"100566290","active-surveillance-program-in-thyroid-nodules-100566290","NCT06653257","Active Surveillance Program in Thyroid Nodules","Outcomes of a 5-Year Active Surveillance Program in Bethesda IV-VI Thyroid Nodules","Inclusion Criteria:\n\n1. Patients with thyroid nodules and FNAC with a report corresponding to Bethesda category IV-VI, treated at the following health centers: HUSVF, HAMA, Center of Excellence in Head and Neck Diseases - CEXCA, Somer Clinic.\n2. Patients classified as low-risk tumors (intrathyroidal, with no evidence of locoregional or distant metastasis).\n3. Patients not subjected to thyroidectomy as the initial treatment.\n\nExclusion Criteria:\n\n* 1\\. Patients with a second head and neck cancer. 2. Patients with clinical or imaging evidence of thyroid malignancy with lymph node or distant metastasis confirmed by pathology.",{"count":121,"type":21},"Overview This study focuses on thyroid nodules, specifically the Bethesda IV-VI categories, which have uncertain or suspicious malignancy. The idea is to observe and monitor these nodules instead of opting for immediate surgery, a practice known as active surveillance. The main goal of active surveillance is to avoid unnecessary surgeries, which can lead to complications like nerve damage or hypoparathyroidism.\n\nProblem and Objectives Thyroid nodules in these Bethesda categories can be cancerous, but not all require immediate removal. Active surveillance tracks nodule growth and other changes using regular ultrasounds and clinical checkups. This approach is gaining popularity, especially in Japan, Europe, and the U.S., but there's still a need for more data, particularly in Latin America.\n\nThe primary objectives of the study are:\n\nGeneral: To describe the clinical and imaging characteristics of patients with Bethesda IV-VI nodules under active surveillance.\n\nSpecific: To measure surgery rates, reasons for surgery, and how long patients can avoid surgery.\n\nMethodology This study is a multicenter historical cohort study, which will look at patients treated from 2019 to 2023 in different hospitals. Patients included in the study are those with Bethesda IV-VI thyroid nodules, who are over 18 and have been managed without immediate thyroid surgery. Data will be collected from medical records and imaging reports, and patients will be followed up to document any changes in their nodules, including growth or metastasis.\n\nExpected Impact The study aims to determine whether active surveillance can safely delay or avoid surgery for selected patients. It could have a significant impact on clinical decision-making, improving patient outcomes and reducing unnecessary surgeries, especially within the Colombian healthcare system. If successful, this approach could reduce costs and improve the quality of life for patients with thyroid nodules.\n\nEthical Considerations The study will follow ethical guidelines, ensuring patient confidentiality and classifying the research as \"no-risk,\" meaning it involves minimal risk to the participants.",[25],[455,456,457,458],"thyroid","nodule","bethesda","active surveillance","2024-10-27",{"date":461,"type":40},"2024-10-29",{"date":463,"type":21},"2024-11-01",{"date":465,"type":21},"2026-07-01",{"name":467,"class":47},"Centro de Excelencia en Enfermedades de Cabeza y Cuello",4,{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":288,"sex":16,"minAge":17,"maxAge":475,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":48},"100563010","health-related-quality-of-life-and-emotions-in-patients-with-thyroid-nodules-100563010","NCT06610604","Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules","Inclusion Criteria:\n\n* Clinical diagnosis of benign thyroid nodules or papillary thyroid carcinoma ;\n* underwent microwave ablation or thyroidectomy;\n* ability to understand and cooperate with the survey\n\nExclusion Criteria:\n\n* serious primary diseases in the liver, kidney, hematopoietic, or endocrine systems；\n* a history of mental illness, personality disorders, cognitive impairments, or organic brain disease","70 Years",{"count":477,"type":21},500,"The purpose of this observational research is to evaluate and compare the health-related quality of life and emotional well-being of patients with thyroid nodules before and after treatment. This is a data collection study by allowing investigators to access information generated before and after treatment.",[25],[481,482,483,484,485,486,487,488],"quality of life","anxiety","depression","spiritual health","thermal ablation","microwave ablation","thyroid nodules","papillary thyroid carcinoma","2024-09-22",{"date":491,"type":40},"2024-09-24",{"date":493,"type":40},"2022-08-01",{"date":495,"type":21},"2027-12",{"name":497,"class":47},"Ming-an Yu",{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":288,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":506,"targetDuration":508,"studyType":22,"phases":4,"briefSummary":509,"conditions":510,"keywords":514,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":48},"100557560","preoperative-hemogram-parameters-and-braf-molecular-test-detected-by-bethesda-3-cytology-100557560","NCT06539702","Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.","To Reveal the Predictive Value of Preoperative Hemogram Parameters and BRAF Molecular Test in Predicting Malignancy in Cases With Thyroid Nodules Detected by Bethesda 3 Cytology.","Bethesda3","Inclusion Criteria:\n\n1. Patients between the ages of 18 -75\n2. Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy\n\nExclusion Criteria:\n\n1. Patients over 18 years old and under 75 years old\n2. Patients with malignancy detected in another focus with preoperative Bethesda III FNAC\n3. Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy\n4. Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing",{"count":507,"type":21},120,"7 Days","The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology.\n\nThe secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology.\n\nPrimary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.",[511,512,25,513],"Blood Platelet Disorder","BRAF V600E","Cytologic Atypia",[515,516,517,518],"Thyroid","carcinoma","Bethesda 3","BRAF","2024-08-01",{"date":521,"type":40},"2024-08-06",{"date":523,"type":40},"2024-07-20",{"date":525,"type":21},"2024-08-15",{"name":527,"class":47},"Saglik Bilimleri Universitesi",{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":48},"100446034","cognition-and-qol-after-thyroid-surgery-100446034","NCT05088187","Cognition and QoL After Thyroid Surgery","Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules","Inclusion Criteria:\n\n* Age \\>18 years old, indication for surgery because of a thyroid nodule Bethesda IV-VI\n* Able to read and understand the Swedish language\n* Access to desktop computer or laptop with internet connection\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* A previous diagnosis of (auto-immune) hypothyroidism\n* A previous cancer diagnosis (excluding basal cell cancer of the skin)\n* Indications for surgery other than (solely) a thyroid nodule (i.e., concomitant Graves)\n* A diagnosis of medullary and anaplastic thyroid cancer",{"count":536,"type":21},320,"The development of cognitive dysfunction can profoundly affect HR-QoL as well as the possibility of societal participation and ability to work, and thereby relevantly impacts prospects for cancer survivorship. The aim of the study is to obtain improved understanding of the scope and magnitude of objective cognitive dysfunction in DTC survivors, and its relation to subjective cognitive dysfunction, thyroid hormone levels, physical activity and HRQoL. This is done in a prospective study where patients operated for a thyroid nodule (Bethesda IV-VI, i.e., benign \\[goitre with nodule and fibroadenomas\\], low-risk DTC and intermediate-high risk DTC) are included and asked to serially perform online neuropsychological testing as well as to complete questionnaires related to HR-QoL, physical activity and additional psychological and physical complaints. Blood is analysed for levels of thyroid hormones and systemic inflammation.",[25,28,539,540,541],"Cognitive Decline","Survivorship","Symptoms, Cognitive","2023-01-16",{"date":544,"type":40},"2023-01-18",{"date":546,"type":40},"2023-01-17",{"date":548,"type":21},"2026-11-01",{"name":550,"class":47},"Karolinska University Hospital",{"id":552,"slug":553,"hasResults":11,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":561,"conditions":562,"keywords":563,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":575,"locationsCount":48},"100472168","assessment-the-cancer-risk-of-indeterminate-thyroid-nodules-through-integration-of-clinical-ultrasonographic-and-multiomic-features-100472168","NCT05428371","Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features","A Novel, Multimodal, Machine-learning Grounded Approach to Assess the Oncological Risk of Indeterminate Thyroid Nodules","THYOMICS","Inclusion Criteria:\n\n* Patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda Classification of thyroid nodules)\n\nExclusion Criteria:\n\n* Patients with concomitant thyroid nodules of Bethesda Class V or Class VI\n* Patients with preoperative diagnosis of lymph node metastases of central or lateral neck compartment\n* Patients with distant metastases",{"count":560,"type":21},256,"Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.",[25,28],[564,565,566,567,568],"Thyroid carcinoma","Indeterminate thyroid nodule","Genomics","Proteomics","Metabolomics","2022-06-16",{"date":571,"type":40},"2022-06-23",{"date":573,"type":21},"2023-01-01",{"date":110,"type":21},{"name":576,"class":47},"University of Cagliari",{"id":578,"slug":579,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":48},"100337661","hrqol-in-thyroid-cancer-and-thyroid-tumours-100337661","NCT03676348","HRQOL in Thyroid Cancer and Thyroid Tumours","Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer","Inclusion Criteria:\n\n* planned hemi- or total thyroidectomy at the ENT-Department of Oslo University Hospital\n* tumour in the thyroid gland With fine needle aspiration results of Bethesda 3-6, or other clinical manifestations suspicious of cancer.\n* ability to understand and Complete the quesitionnaires\n* informed consent to participation\n\nExclusion Criteria:\n\n* unable to Complete or understand the questionnaires\n* age below 18 years\n* thyroid surgery within the last 2 years\n* thyroid surgery on other indications than listed above\n* participants With postoperative external radiotherapy",{"count":94,"type":21},"Background: Most patients with thyroid cancer have a long life expectancy, and it has been assumed among health professionals that therefore the quality of life (QOL) is good. Some European studies have shown that the quality of life among thyroid cancers is worse than the general population, and almost as low as other cancer diagnoses, with a worse prognosis and a more burdening treatment.\n\nAim: To examine prospectively the quality of life in participants undergoing diagnostic thyroid surgery and participants undergoing surgery for certain thyroid cancer. By examining both groups we wish to find answers if quality of life is affected, and if so - mostly affected by the diagnosis or the surgery itself.\n\nMethods: Participants enroll the study after informed consent, and quality of life will be assessed using quality of life questionnaires EORTC QLQ C30, EORTC THY 47 and EORTC FA12 before surgery, and 6 and 12 months after surgery. This study will form two main groups of participants; with and without thyroid cancer.",[25,28,587],"Quality of Life",[481,589,590,591,592,593,594],"health related quality of life","thyroid cancer","thyroid nodule","thyroid neoplasm","thyroid surgery","patient reported outcome measurements","2022-02-25",{"date":597,"type":40},"2022-03-11",{"date":599,"type":40},"2018-01-25",{"date":601,"type":21},"2028-04",{"name":603,"class":47},"Oslo University Hospital"]